Sales grew 38% year over year, driven by volume growth from weight-loss and diabetes drugs Zepbound and Mounjaro, Lilly said. Zepbound sales in the quarter was $3.4 billion and Mounjaro sales came in at $5.2 billion, beating estimates of $3 billion and $4.7 billion, according to FactSet estimates.

Lilly’s stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and outlook.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.